Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to determine the optimal concentration of grass pollen allergens inducing rhinoconjunctivitis in subjects allergic to grass pollen in ALYATEC allergen exposure chamber. Four concentrations of grass pollen allergen (Phl p 5) are tested during 3-hour exposures: 0, 30, 60 and 90 ng/m3.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06104293
Study type Interventional
Source Alyatec
Contact
Status Completed
Phase N/A
Start date November 16, 2022
Completion date April 6, 2023

See also
  Status Clinical Trial Phase
Completed NCT03290248 - Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis Phase 1/Phase 2
Completed NCT04878237 - Kinetics of Nasal Cytokine Responses to Mechanical Stimulation N/A
Completed NCT04802616 - The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells Phase 3
Active, not recruiting NCT05297760 - Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract Phase 1/Phase 2
Recruiting NCT06061848 - Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT Phase 2/Phase 3
Not yet recruiting NCT04700852 - Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis N/A
Completed NCT05037955 - ILIT: Follow-up of Rhinitis Quality of Life
Active, not recruiting NCT05191186 - Documentation of Efficacy of Intralymphatic Allergen Immunotherapy Phase 3
Completed NCT04210193 - Is Intralymphatic Allergen Immunotherapy Effective and Safe? Phase 2/Phase 3
Completed NCT01953471 - Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2) N/A